Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Lin Xu, Chi-Chi Peng, Kate Dawson, Scott Stecher, James Woodworth & Chandra Prakash. (2023) Metabolism, pharmacokinetics and excretion of [14C]dimethyl fumarate in healthy volunteers: an example of xenobiotic biotransformation following endogenous metabolic pathways. Xenobiotica 53:3, pages 163-172.
Read now
Read now
Carolyn H Goldschmidt & Le H Hua. (2020) Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy. Degenerative Neurological and Neuromuscular Disease 10, pages 29-38.
Read now
Read now
Cristina Valencia-Sanchez & Jonathan L. Carter. (2020) An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis. Expert Opinion on Pharmacotherapy 21:12, pages 1399-1405.
Read now
Read now
Catalina Coclitu, Cris S. Constantinescu & Radu Tanasescu. (2016) The future of multiple sclerosis treatments. Expert Review of Neurotherapeutics 16:12, pages 1341-1356.
Read now
Read now
Nikolaos Grigoriadis, Michael Linnebank, Nektaria Alexandri, Sarah Muehl & Günther F. L. Hofbauer. (2016) Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion. Expert Opinion on Pharmacotherapy 17:15, pages 2085-2095.
Read now
Read now
Duvyanshu Dubey, Bernd C Kieseier, Hans P Hartung, Bernhard Hemmer, Clemens Warnke, Til Menge, William A Miller-Little & Olaf Stuve. (2015) Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Review of Neurotherapeutics 15:4, pages 339-346.
Read now
Read now
Articles from other publishers (18)
Ramachandrapuram KiranjyothiMahalingam BalakrishnanKothapalli Bannoth Chandrasekhar. (2021) Stability Indicating RP-HPLC Method Development and Validation for Estimation of Diroximel Fumarate in bulk and its dosage forms. Research Journal of Pharmacy and Technology, pages 2603-2607.
Crossref
Crossref
Chiara Zecca, Adam Czaplinski, Christophe Henny, Liliane Petrini, Andreas Beeler & Claudio Gobbi. (2020) SwissTecLive: effectiveness and safety of dimethyl fumarate in the treatment of RRMS in the Swiss clinical practice setting. Heliyon 6:12, pages e05819.
Crossref
Crossref
Patrycja Michalska & Rafael León. (2020) When It Comes to an End: Oxidative Stress Crosstalk with Protein Aggregation and Neuroinflammation Induce Neurodegeneration. Antioxidants 9:8, pages 740.
Crossref
Crossref
Farinaz SafaviRodolfo ThomeZichen LiGuang-Xian ZhangAbdolmohamad Rostami. (2020) Dimethyl fumarate suppresses granulocyte macrophage colony-stimulating factor–producing Th1 cells in CNS neuroinflammation. Neurology Neuroimmunology & Neuroinflammation 7:4.
Crossref
Crossref
Diego Lastra, Raquel Fernández-Ginés, Gina Manda & Antonio Cuadrado. 2021. Reactive Oxygen Species. Reactive Oxygen Species
93
141
.
K. Kridin, E.H. Kowalski, D. Kneiber, R. Laufer‐Britva & K.T. Amber. (2019) From bench to bedside: evolving therapeutic targets in autoimmune blistering disease. Journal of the European Academy of Dermatology and Venereology 33:12, pages 2239-2252.
Crossref
Crossref
Randa Sghaier, Thomas Nury, Valerio Leoni, Claudio Caccia, Jean-Paul Pais De Barros, Ameur Cherif, Anne Vejux, Thibault Moreau, Khalifa Limem, Mohammad Samadi, John J. Mackrill, Ahmed Slaheddine Masmoudi, Gérard Lizard & Amira Zarrouk. (2019) Dimethyl fumarate and monomethyl fumarate attenuate oxidative stress and mitochondrial alterations leading to oxiapoptophagy in 158N murine oligodendrocytes treated with 7β-hydroxycholesterol. The Journal of Steroid Biochemistry and Molecular Biology 194, pages 105432.
Crossref
Crossref
Mehrdad Gholamzad, Masoumeh Ebtekar, Mehdi Shafiee Ardestani, Maryam Azimi, Zeinab Mahmodi, Mohammad Javad Mousavi & Saeed Aslani. (2018) A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflammation Research 68:1, pages 25-38.
Crossref
Crossref
Ying Fu & Yaping Yan. (2018) Emerging Role of Immunity in Cerebral Small Vessel Disease. Frontiers in Immunology 9.
Crossref
Crossref
Robbert-Jan Gieselbach, Annemarie H. Muller-Hansma, Martijn T. Wijburg, Marjolein S. de Bruin-Weller, Bob W. van Oosten, Dennis J. Nieuwkamp, Frank E. Coenjaerts, Mike P. Wattjes & Jean-Luc Murk. (2017) Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. Journal of Neurology 264:6, pages 1155-1164.
Crossref
Crossref
Rui Li, Ayman Rezk, Mathab Ghadiri, Felix Luessi, Frauke Zipp, Hulun Li, Paul S. Giacomini, Jack Antel & Amit Bar-Or. (2017) Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis. The Journal of Immunology 198:2, pages 691-698.
Crossref
Crossref
Giulio Disanto, Pascal Benkert, Johannes Lorscheider, Stefanie Mueller, Jochen Vehoff, Chiara Zecca, Simon Ramseier, Lutz Achtnichts, Oliver Findling, Krassen Nedeltchev, Ernst-Wilhelm Radue, Till Sprenger, Christoph Stippich, Tobias Derfuss, Jean-François Louvion, Christian P. Kamm, Heinrich P. Mattle, Christoph Lotter, Renaud Du Pasquier, Myriam Schluep, Caroline Pot, Patrice H. Lalive, Özgür Yaldizli, Claudio Gobbi, Ludwig Kappos & Jens Kuhle. (2016) The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLOS ONE 11:3, pages e0152347.
Crossref
Crossref
Othman Al-Sawaf, Tim Clarner, Athanassios Fragoulis, Yuet Wai KanThomas Pufe, Konrad Streetz & Christoph Jan Wruck. (2015) Nrf2 in health and disease: current and future clinical implications. Clinical Science 129:12, pages 989-999.
Crossref
Crossref
Fiona E. MutterB. Kevin ParkIan M. Copple. (2015) Value of monitoring Nrf2 activity for the detection of chemical and oxidative stress. Biochemical Society Transactions 43:4, pages 657-662.
Crossref
Crossref
S.G. Meuth. (2015) Zeigen die neuen oralen Therapien Vorteile in der Basistherapie der Multiplen Sklerose? ProDo new oral therapies show advantages in the basal therapy of multiple sclerosis? Pro. Der Nervenarzt 86:4, pages 491-491.
Crossref
Crossref
J. Havla, T. Kümpfel & R. Hohlfeld. (2015) Immuntherapie der multiplen SkleroseImmunotherapies for multiple sclerosis. Der Internist 56:4, pages 432-445.
Crossref
Crossref
Roberto Bomprezzi. (2015) Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview. Therapeutic Advances in Neurological Disorders 8:1, pages 20-30.
Crossref
Crossref
Oscar Fernandez. (2014) BG-12 (dimethyl fumarate) in the treatment of multiple sclerosis. Clinical Investigation 4:5, pages 441-451.
Crossref
Crossref